Drug Profile

YOLT 202

Alternative Names: SERP-01; YOLT-202

Latest Information Update: 23 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator YolTech Therapeutics
Class Gene therapies
Mechanism of Action Gene transference; SERPINA1 protein expression modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Alpha 1-antitrypsin deficiency
New Molecular Entity No

Highest Development Phases

Phase 0 Alpha 1-antitrypsin deficiency

Most Recent Events

15 Sep 2026 YOLT 202 receives Regenerative Medicine Advanced Therapy (RMAT) status for Alpha 1-antitrypsin deficiency in USA, prior to September 2026
15 Sep 2026 YolTech Therapeutics plans a phase II/III clinical trial for Alpha 1-antitrypsin deficiency in USA and other countries in late 2026 or early 2027 (IV)
30 Jun 2026 YOLT 202 licensed to Serapha worldwide excluding china

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com